ArticleSeminars in fetal & neonatal medicine2009
Prevention of bronchopulmonary dysplasia.
Article in Seminars in fetal & neonatal medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 51 citations in OpenAlex.
- Lucinactant, a Synthetic Surfactant for the Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19: Phase 1/2A Trial.JMIR formative research · 2026Trial
- Real-world use of hydrocortisone and dexamethasone in the prevention and treatment of bronchopulmonary dysplasia in preterm infants <32 weeks: a nine-year cohort study.Frontiers in pediatrics · 2026Article
- Hyperoxia-induced lung structure-function relation, vessel rarefaction, and cardiac hypertrophy in an infant rat model.Journal of translational medicine · 2019Article
- Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches.Clinical medicine insights. Pediatrics · 2018Review
- Less invasive ventilation in extremely low birth weight infants from 1997 to 2011: survey versus evidence.European journal of pediatrics · 2015Article
- Assessment of inhibited alveolar-capillary membrane structural development and function in bronchopulmonary dysplasia.Birth defects research. Part A, Clinical and molecular teratology · 2014Review
- An update on pharmacologic approaches to bronchopulmonary dysplasia.Seminars in perinatology · 2013Review
- Early caffeine therapy and clinical outcomes in extremely preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2013Article
- Perinatal inflammation and lung injury.Seminars in fetal & neonatal medicine · 2012Review
- Current pharmacologic approaches for prevention and treatment of bronchopulmonary dysplasia.International journal of pediatrics · 2012Article
- Aberrant signaling pathways of the lung mesenchyme and their contributions to the pathogenesis of bronchopulmonary dysplasia.Birth defects research. Part A, Clinical and molecular teratology · 2012Review
- Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?Pediatrics · 2011Review
- Decreased free water clearance is associated with worse respiratory outcomes in premature infants.PloS one · 2011Article
- Respiratory outcomes and atopy in school-age children who were preterm at birth, with and without bronchopulmonary dysplasia.Clinics (Sao Paulo, Brazil) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Considerable effort has been devoted to the development of strategies to reduce the incidence of bronchopulmonary dysplasia (BPD), including use of medications, nutritional therapies, and respiratory care practices. Unfortunately, most of these strategies have not been successful. To date, the only two treatments developed specifically to prevent BPD whose efficacy is supported by evidence from randomized, controlled trials are the parenteral administration of vitamin A and corticosteroids. Two other therapies, the use of caffeine for the treatment of apnea of prematurity and aggressive phototherapy for the treatment of hyperbilirubinemia, were evaluated for the improvement of other outcomes and found to reduce BPD. Cohort studies suggest that the use of continuous positive airway pressure as a strategy for avoiding mechanical ventilation might also be beneficial. Other therapies reduce lung injury in animal models but do not appear to reduce BPD in humans. The benefits of the efficacious therapies have been modest, with an absolute risk reduction in the 7-11% range. Further preventive strategies are needed to reduce the burden of this disease. However, each will need to be tested in randomized, controlled trials, and the expectations of new therapies should be modest reductions of the incidence of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.